The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients

Shin, Eun Kyong; Choi, Hyo Young; Hayes, D. Neil

doi:10.4178/epih.e2021035

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to data from a large New York City cohort, DM increased the risk for critical illness (defined as a composite of ICU admission, need of mechanical ventilation, discharge to hospice, or death) among COVID-19-infected patients, but the relationship was attenuated in the fully adjusted model ( 87 ). Similar were the results of another study from Korea; DM was not an independent predictor of severe disease (defined according to oxygen needs, multiorgan failure/ECMO, and death) after adjustment for age, sex, and comorbidities (OR, 1.08; 0.82–1.42) ( 67 ). Tchang et al.…”

Section: Dm and Covid-19 Infection Outcomessupporting

confidence: 82%

“…Additionally, in a large cohort from Brazil, hospitalized COVID-19-infected patients with DM were more likely to die than patients without DM ( 66 ). According to a study from Korea, DM independently associated with mortality in hospitalized patients with COVID-19 infection ( 67 ). Evidence from Turkey as well highlights DM as a risk factor for death in COVID-19-infected hospitalized patients in general ( 59 ) and in the elderly ( 68 ).…”

Section: Dm and Covid-19 Infection Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review

Tzeravini¹,

Stratigakos²,

Siafarikas³

et al. 2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

It was previously reported that subjects with diabetes mellitus (DM) are more vulnerable to several bacterial or viral infections. In the era of coronavirus disease 2019 (COVID-19) pandemic, it is reasonable to wonder whether DM is a risk factor for COVID-19 infection, too. It is not yet clear whether DM increases the risk for contracting COVID-19 infection or not. However, patients with DM when infected are more likely to develop severe or even fatal COVID-19 disease course than patients without DM. Certain characteristics of DM patients may also deteriorate prognosis. On the other hand, hyperglycemia per se is related to unfavorable outcomes, and the risk may be higher for COVID-19 subjects without pre-existing DM. In addition, individuals with DM may experience prolonged symptoms, need readmission, or develop complications such as mucormycosis long after recovery from COVID-19; close follow-up is hence necessary in some selected cases. We here present a narrative review of the literature in order to set light into the relationship between COVID-19 infection and DM/hyperglycemia.

show abstract

Section: Dm and Covid-19 Infection Outcomessupporting

confidence: 82%

Section: Dm and Covid-19 Infection Outcomesmentioning

confidence: 99%

The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review

Tzeravini¹,

Stratigakos²,

Siafarikas³

et al. 2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

show abstract

Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis

Finnerty,

Hussain,

Ponnuswamy

et al. 2023

BMC Pulm Med

View full text Add to dashboard Cite

Background Factors predisposing to increased mortality with COVID-19 infection have been identified as male sex, hypertension, obesity, and increasing age. Early studies looking at airway diseases gave some contradictory results. The purpose of our study was to determine global variation in studies in patients hospitalized with COVID-19 in the prevalence of COPD and asthma; and to determine whether the presence of asthma or COPD affected mortality in the same hospital population. Methods A systematic review and meta-analysis of the published literature of COPD and asthma as co-morbidities in patients hospitalized with COVID-19 was performed, looking firstly at the prevalence of these diseases in patients hospitalized with COVID-19, and secondly at the relative risk of death from any cause for patients with asthma or COPD. Results Prevalence of both airway diseases varied markedly by region, making meaningful pooled global estimates of prevalence invalid and not of clinical utility. For individual studies, the interquartile range for asthma prevalence was 4.21 to 12.39%, and for COPD, 3.82 to 11.85%. The relative risk of death with COPD for patients hospitalized with COVID-19 was 1.863 (95% CI 1.640–2.115), while the risk with asthma was 0.918 (95% CI 0.767 to 1.098) with no evidence of increased mortality. Conclusions For asthma and COPD, prevalence in patients hospitalized with COVID-19 varies markedly by region. We found no evidence that asthma predisposed to increased mortality in COVID-19 disease. For COPD, there was clear evidence of an association with increased mortality. Trial registration The trial was registered with PROSPERO: registration number CRD42021289886.

show abstract

SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

Smadi,

Kaburis,

Schnapper

et al. 2023

Br J Psychiatry

View full text Add to dashboard Cite

Background People with neurodegenerative disease and mild cognitive impairment (MCI) may have an elevated risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may be disproportionally affected by coronavirus disease 2019 (COVID-19) once infected. Aims To review all eligible studies and quantify the strength of associations between various pre-existing neurodegenerative disorders and both SARS-CoV-2 susceptibility and COVID-19 illness course and outcome. Method Pre-registered systematic review with frequentist and Bayesian meta-analyses. Systematic searches were executed in PubMed, Web of Science and preprint servers. The final search date was 9 January 2023. Odds ratios (ORs) were used as measures of effect. Results In total, 136 primary studies (total sample size n = 97 643 494), reporting on 268 effect-size estimates, met the inclusion criteria. The odds for a positive SARS-CoV-2 test result were increased for people with pre-existing dementia (OR = 1.83, 95% CI 1.16–2.87), Alzheimer's disease (OR = 2.86, 95% CI 1.44–5.66) and Parkinson's disease (OR = 1.65, 95% CI 1.34–2.04). People with pre-existing dementia were more likely to experience a relatively severe COVID-19 course, once infected (OR = 1.43, 95% CI 1.00–2.03). People with pre-existing dementia or Alzheimer's disease were at increased risk for COVID-19-related hospital admission (pooled OR range: 1.60–3.72). Intensive care unit admission rates were relatively low for people with dementia (OR = 0.54, 95% CI 0.40–0.74). All neurodegenerative disorders, including MCI, were at higher risk for COVID-19-related mortality (pooled OR range: 1.56–2.27). Conclusions Our findings confirm that, in general, people with neurodegenerative disease and MCI are at a disproportionally high risk of contracting COVID-19 and have a poor outcome once infected.

show abstract

The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients

Cited by 3 publications

References 38 publications

The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review

The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review

Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis

SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

Contact Info

Product

Resources

About